ATE407125T1 - Pharmazeutische zusammenstellungen aus tachykinin antagonisten und einen serotonin-wiederaufname hemmer - Google Patents

Pharmazeutische zusammenstellungen aus tachykinin antagonisten und einen serotonin-wiederaufname hemmer

Info

Publication number
ATE407125T1
ATE407125T1 AT04076650T AT04076650T ATE407125T1 AT E407125 T1 ATE407125 T1 AT E407125T1 AT 04076650 T AT04076650 T AT 04076650T AT 04076650 T AT04076650 T AT 04076650T AT E407125 T1 ATE407125 T1 AT E407125T1
Authority
AT
Austria
Prior art keywords
rupup
serotonin
inhibitor
pharmaceutical compositions
tachykinin antagonists
Prior art date
Application number
AT04076650T
Other languages
English (en)
Inventor
Sergio Melotto
Mauro Corsi
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE407125T1 publication Critical patent/ATE407125T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT04076650T 1999-10-07 2000-10-05 Pharmazeutische zusammenstellungen aus tachykinin antagonisten und einen serotonin-wiederaufname hemmer ATE407125T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9923748.9A GB9923748D0 (en) 1999-10-07 1999-10-07 Chemical compounds

Publications (1)

Publication Number Publication Date
ATE407125T1 true ATE407125T1 (de) 2008-09-15

Family

ID=10862304

Family Applications (3)

Application Number Title Priority Date Filing Date
AT04076650T ATE407125T1 (de) 1999-10-07 2000-10-05 Pharmazeutische zusammenstellungen aus tachykinin antagonisten und einen serotonin-wiederaufname hemmer
AT04076632T ATE435215T1 (de) 1999-10-07 2000-10-05 Piperazine verbindungen als tachykinin-hemmer
AT00969414T ATE270664T1 (de) 1999-10-07 2000-10-05 Piperazin verbindungen als tachykinin- antagonisten

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT04076632T ATE435215T1 (de) 1999-10-07 2000-10-05 Piperazine verbindungen als tachykinin-hemmer
AT00969414T ATE270664T1 (de) 1999-10-07 2000-10-05 Piperazin verbindungen als tachykinin- antagonisten

Country Status (33)

Country Link
US (6) US6951861B1 (de)
EP (3) EP1218359B1 (de)
JP (1) JP4776844B2 (de)
KR (2) KR100817373B1 (de)
CN (1) CN100413850C (de)
AR (2) AR025975A1 (de)
AT (3) ATE407125T1 (de)
AU (1) AU768780B2 (de)
BR (1) BR0014541A (de)
CA (1) CA2386515C (de)
CO (1) CO5251467A1 (de)
CY (2) CY1110172T1 (de)
CZ (1) CZ302340B6 (de)
DE (3) DE60012031T2 (de)
DK (3) DK1460066T3 (de)
ES (3) ES2312917T3 (de)
GB (1) GB9923748D0 (de)
HK (3) HK1052506B (de)
HU (1) HUP0203136A3 (de)
IL (2) IL148964A0 (de)
MX (1) MXPA02003515A (de)
MY (1) MY130907A (de)
NO (1) NO323776B1 (de)
NZ (2) NZ531127A (de)
PE (1) PE20010741A1 (de)
PL (1) PL201191B1 (de)
PT (3) PT1218359E (de)
SI (3) SI1218359T1 (de)
TN (1) TNSN00194A1 (de)
TR (1) TR200200936T2 (de)
TW (1) TWI225485B (de)
WO (1) WO2001025219A2 (de)
ZA (1) ZA200202589B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048581A2 (en) * 1999-02-18 2000-08-24 Novartis Ag Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0108595D0 (en) 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
GB0124463D0 (en) * 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
DE10209145A1 (de) * 2002-03-01 2003-09-04 Bayer Cropscience Ag Halogenbenzole
AU2003243353A1 (en) * 2002-05-29 2003-12-19 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
JP4079727B2 (ja) * 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
EP1594574A2 (de) * 2003-01-27 2005-11-16 Glaxo Group Limited Nk1-rezeptor-antagonisten zur behandlung der funktionalen dyspepsie
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
EP1638935A1 (de) * 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonisten
US20060148781A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder in a non-human mammal
US20070142367A1 (en) * 2003-11-10 2007-06-21 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
US20050113365A1 (en) * 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
US20060148783A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US7390905B2 (en) * 2003-11-28 2008-06-24 Mitsubishi Tanabe Pharma Corporation Piperidine compound and process for preparing the same
EP1705176A4 (de) * 2004-01-14 2009-06-03 Takeda Pharmaceutical Carbonsäureamidderivat und dessen anwendung
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP1943216B1 (de) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamidderivate als natriumkanalmodulatoren
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP4904945B2 (ja) 2006-06-30 2012-03-28 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体の製造方法
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
EP2117538A1 (de) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmazeutische zusammensetzungen mit 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP5510040B2 (ja) * 2010-04-28 2014-06-04 セントラル硝子株式会社 光学活性（ｒ）−１−（４−フルオロフェニル）エチルアミンを得る光学分割
WO2012175434A1 (en) 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
RU2631319C2 (ru) 2012-02-22 2017-09-21 Лео Фарма А/С Новые соединения - антагонисты рецептора нейрокинина 1
WO2015024203A1 (en) * 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
ES2813596T3 (es) 2015-12-07 2021-03-24 Kissei Pharmaceutical Antagonista del receptor NK1
BR112019021125A2 (pt) 2017-04-10 2020-05-12 Chase Therapeutics Corporation Combinação de antagonista de nk1 e método para tratamento de sinucleinopatias
MA49524A (fr) 2017-06-30 2021-05-26 Chase Therapeutics Corp Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
JP2020536870A (ja) 2017-10-05 2020-12-17 バイオジェン インコーポレイテッド アルファカルボキサミドピロリジン誘導体の調製方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
US4379152A (en) 1974-05-09 1983-04-05 Toyama Chemical Co., Ltd. Cephalosporins
US4087424A (en) 1974-05-09 1978-05-02 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4219554A (en) 1974-05-09 1980-08-26 Toyama Chemical Company, Limited Novel penicillins and cephalosporins and process for producing same
US4110327A (en) 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4327097A (en) 1974-05-09 1982-04-27 Toyama Chemical Co., Ltd. Novel penicillins
US4410522A (en) 1974-05-09 1983-10-18 Toyama Chemical Co., Ltd. Cephalosporins
US4112090A (en) 1974-05-09 1978-09-05 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel penicillin
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en) 1987-04-23 1987-05-28 Beecham Group Plc Compounds
GB8713061D0 (en) 1987-06-04 1987-07-08 Beecham Group Plc Compounds
US5109014A (en) 1990-12-10 1992-04-28 Jacobson Richard M N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
EP0916346A3 (de) 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 Rezeptor Antagonisten und 5HT3 Rezeptor Antagonisten zur Behandlung von Emesis
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
WO1996003378A1 (fr) 1994-07-26 1996-02-08 Sankyo Company, Limited Derives d'amide n-phenyle et d'uree
DE19520499C2 (de) 1994-09-17 2003-06-18 Boehringer Ingelheim Kg Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
US5696123A (en) 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
EP0709375B1 (de) 1994-10-25 2005-05-18 AstraZeneca AB Therapeutisch wirksame Heterocyclen
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5700801A (en) 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
AU4432496A (en) 1994-12-23 1996-07-19 Dr. Karl Thomae Gmbh Piperazine derivatives, medicaments containing the same, their use and process for preparing the same
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en) 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
CA2249599A1 (en) 1996-04-03 1997-10-09 Dong D. Wei Inhibitors of farnesyl-protein transferase
AU707139B2 (en) 1996-04-03 1999-07-01 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU715667B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
AU3716997A (en) * 1996-07-17 1998-02-09 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en) 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
WO1998024443A1 (en) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating bipolar disorders
US6114315A (en) 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
US5977104A (en) 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
EP1014984A1 (de) 1997-08-27 2000-07-05 Merck & Co., Inc. Prenyl-protein transferase inhibitoren
DE69824037T2 (de) 1997-11-24 2005-06-02 Merck & Co., Inc. Beta-alanin-derivate als zell-adhäsions-inhibitoren
AU768652B2 (en) * 1998-12-14 2003-12-18 Astellas Pharma Inc. Piperazine derivatives
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
WO2001030348A1 (en) * 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
CY1110172T1 (el) 2015-01-14
US7071196B2 (en) 2006-07-04
TWI225485B (en) 2004-12-21
CZ302340B6 (cs) 2011-03-23
US20060122192A1 (en) 2006-06-08
NZ518144A (en) 2004-04-30
AR025975A1 (es) 2002-12-26
PL201191B1 (pl) 2009-03-31
ATE270664T1 (de) 2004-07-15
CN100413850C (zh) 2008-08-27
GB9923748D0 (en) 1999-12-08
JP4776844B2 (ja) 2011-09-21
TR200200936T2 (tr) 2002-07-22
ZA200202589B (en) 2003-08-27
HK1065798A1 (en) 2005-03-04
US7345041B2 (en) 2008-03-18
DE60012031T2 (de) 2005-07-07
US7625904B2 (en) 2009-12-01
IL148964A0 (en) 2002-11-10
HK1052506A1 (en) 2003-09-19
IL148964A (en) 2007-02-11
SI1218359T1 (en) 2005-02-28
KR100857671B1 (ko) 2008-09-08
CA2386515C (en) 2011-06-07
MY130907A (en) 2007-07-31
KR20020038800A (ko) 2002-05-23
US6642240B2 (en) 2003-11-04
ES2222927T3 (es) 2005-02-16
SI1454901T1 (sl) 2009-02-28
HUP0203136A2 (hu) 2003-02-28
US20040048862A1 (en) 2004-03-11
PT1460066E (pt) 2009-09-10
AU7913900A (en) 2001-05-10
SI1460066T1 (sl) 2009-12-31
NO20021637D0 (no) 2002-04-05
WO2001025219A2 (en) 2001-04-12
CY1110104T1 (el) 2015-01-14
CN1391564A (zh) 2003-01-15
WO2001025219A3 (en) 2001-12-13
HUP0203136A3 (en) 2003-03-28
DE60042501D1 (de) 2009-08-13
US20030028021A1 (en) 2003-02-06
NO20021637L (no) 2002-06-06
BR0014541A (pt) 2002-09-17
AU768780B2 (en) 2004-01-08
CO5251467A1 (es) 2003-02-28
DK1218359T3 (da) 2004-10-18
PL356261A1 (en) 2004-06-28
TNSN00194A1 (en) 2005-11-10
ES2312917T3 (es) 2009-03-01
PE20010741A1 (es) 2001-07-18
DK1460066T3 (da) 2009-11-02
DE60012031D1 (de) 2004-08-12
ES2329130T3 (es) 2009-11-23
JP2003511377A (ja) 2003-03-25
MXPA02003515A (es) 2002-09-02
DE60040176D1 (de) 2008-10-16
CZ20021166A3 (cs) 2002-11-13
KR100817373B1 (ko) 2008-03-27
KR20070112308A (ko) 2007-11-22
EP1460066B1 (de) 2009-07-01
DK1454901T3 (da) 2009-01-12
US20080249108A1 (en) 2008-10-09
HK1052506B (zh) 2008-12-19
EP1218359A2 (de) 2002-07-03
NZ531127A (en) 2005-11-25
EP1460066A1 (de) 2004-09-22
ATE435215T1 (de) 2009-07-15
EP1454901B1 (de) 2008-09-03
US6951861B1 (en) 2005-10-04
HK1066537A1 (en) 2005-03-24
PT1218359E (pt) 2004-10-29
EP1454901A1 (de) 2004-09-08
CA2386515A1 (en) 2001-04-12
US20040209893A1 (en) 2004-10-21
PT1454901E (pt) 2008-12-12
AR077414A2 (es) 2011-08-24
EP1218359B1 (de) 2004-07-07
NO323776B1 (no) 2007-07-02

Similar Documents

Publication Publication Date Title
ATE407125T1 (de) Pharmazeutische zusammenstellungen aus tachykinin antagonisten und einen serotonin-wiederaufname hemmer
IS2991B (is) Lyfjafræðileg nanóagna samsetning takykínín viðtakamótlyfs
HUP0500880A2 (en) Cxcr3 antagonists and pharmaceutical compositions thereof
DE60144334D1 (de) Myostatin-antagonisten und Verwendungen davon
ATE468324T1 (de) Pharmazeutische zusammensetzung
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
ATE404180T1 (de) Geschmacksmaskierte pharmazeutische partikel
EE04331B1 (et) Kiiresti lahustuv peroraalne ravimvorm
ATE336264T1 (de) Dispergierbare pharmazeutische zusammensetzungen
IL152718A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
FI20001749A (fi) Farmaseuttisia koostumuksia
HUP0301391A3 (en) Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use
MA26882A1 (fr) COMPOSITIONS PHARMACEUTIQUES D'INHIBITEURS ET GLYCOGèNE-PHOSPHORYLASE
HUP0402019A3 (en) Piperidine derivatives useful as ccr5 antagonists and pharmaceutical compositions containing them
HUP0204458A3 (en) Derivatives of quinoline as alpha-2 antagonists and pharmaceutical compositions containing them
DE60225014D1 (de) Pharmazeutische zusammensetzungen von amlodipin und atorvastatin
ATE394375T1 (de) Zusammensetzung enthaltend einen tachykininrezeptor antagonisten und einen serotonin-wiederaufnahmehemmer
DE60329755D1 (de) Basische nichtpeptid-bradykinin-antagonisten und pharmazeutische zusammensetzungen daraus
DE60029340D1 (de) Pharmazeutische zusammenstellungen enthaltend einen p2t rezeptor antagonist und melagatran
DE60021609D1 (de) Pharmazeutische Zusammensetzung enthaltend einen Metabolit von Buspirone
DE60315426D1 (de) Pharmazeutische zusammensetzung enthaltend einen pde4 oder pde3/4 inhibitor und eine histaminrezeptorantagonisten
FI20002768A (fi) Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus
PT1272499E (pt) Composicoes farmaceuticas contendo oligossacaridos e a sua preparacao
ATE424813T1 (de) Pharmazeutische zusammensetzungen mit epinastin und pseudoephedrin
ATE309783T1 (de) Einen histamin h 2 antagonisten enthaltende brausezusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1454901

Country of ref document: EP